Skip to main content
. 2014 Jul 16;5(15):6414–6424. doi: 10.18632/oncotarget.2225

Figure 3. FAPi sensitise immortalised and primary glioma cultures to chemotherapeutic agents irrespective of MGMT status.

Figure 3

A: MTT Temozolomide cytotoxicity assays for U87 and U138 cells treated with the FAPi curcumin, EF-24 or DDN. Solid lines represent cells pre-treated with DMSO and dashed lines represent cells pre-treated with the indicated FAPi. Data shown is the mean from at least 3 independent experiments with error bars representing the standard deviation of the means. B: MTT Temozolomide cytotoxicity assays for two independently derived primary glioma cultures from at least three independent experiments. An additional example is shown in supplementary Figure S2B. Solid, dashed lines and error bars are as described in panel A. C: MTT Temozolomide cytotoxicity assays for T98G cells pre-treated with either DMSO or the FAPi curcumin, EF-24 or DDN. Solid, dashed lines and error bars are as described in panel A.